Corvus Pharmaceuticals, Inc. (CRVS) Tops Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts CRVS Hot Sheet
Join SI Premium – FREE
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23).
For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform
- Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
